Martine Rothblatt, United Therapeutics CEO, sells $5.5M in stock

Martine A. Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics Corp (NASDAQ:UTHR), exercised stock options and subsequently sold shares of the company’s common stock totaling approximately $5.54 million. The transactions occurred on October 22, 2026, and were executed under a pre-arranged 10b5-1 trading plan established on November 7, 2025.

On the specified date, Ms. Rothblatt acquired 9,500 shares of common stock through the exercise of stock options at a price of $117.76 per share, amounting to a total value of $1,118,720. These stock options had vested in equal one-third installments on March 15, 2021, 2022, and 2023.

Following the option exercise, Ms. Rothblatt disposed of 9,500 shares of United Therapeutics common stock. These shares were sold at prices ranging from $562.97 to $590.397 per share, resulting in total proceeds of approximately $5,542,093. The shares involved in these transactions were held indirectly through a family trust, where Ms. Rothblatt shares investment power.The sale comes as United Therapeutics stock trades near its 52-week high of $609.35, with shares up over 40% in the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. Investors seeking deeper insights can access comprehensive Pro Research Reports covering UTHR and 1,400+ other US equities.

After these reported transactions, the number of United Therapeutics common shares held indirectly by Ms. Rothblatt through this specific family trust totaled 324,603. She also holds additional shares directly and indirectly through other family trusts.

In other recent news, United Therapeutics reported a revenue miss of approximately 3% in its second-quarter results, leading BofA Securities to lower its price target on the company to $559 from $613, while maintaining a Neutral rating. This development comes as management decided not to affirm its previous Tyvaso sales guidance. In legal matters, United Therapeutics reached a settlement with Liquidia Technologies, resolving all litigation between the two companies. Liquidia agreed to remove pulmonary hypertension associated with interstitial lung disease from its YUTREPIA label and pay United Therapeutics $380.7 million.

Following this settlement, Jefferies raised its price target on United Therapeutics to $728, maintaining a Buy rating. Cantor Fitzgerald reiterated an Overweight stock rating with a $700 price target after United Therapeutics won a favorable patent ruling concerning its Tyvaso franchise. BTIG upgraded the company to Buy from Neutral, setting a price target of $728, citing a significant legal win that impacts Yutrepia, a competing product. Meanwhile, Goldman Sachs initiated coverage with a Sell rating and a price target of $321, noting the company’s trading metrics and a declining base business.